Human cytomegalovirus latency and reactivation in allogeneic hematopoietic stem cell transplant recipients

L Stern, B Withers, S Avdic, D Gottlieb… - Frontiers in …, 2019 - frontiersin.org
Human cytomegalovirus (HCMV) reactivation is a major infectious cause of morbidity and
mortality after allogeneic hematopoietic stem cell transplantation (HSCT). HCMV is a …

Viral infections in HSCT: detection, monitoring, clinical management, and immunologic implications

C Annaloro, F Serpenti, G Saporiti, G Galassi… - Frontiers in …, 2021 - frontiersin.org
In spite of an increasing array of investigations, the relationships between viral infections
and allogeneic hematopoietic stem cell transplantation (HSCT) are still controversial, and …

Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation

D Zamora, ER Duke, H Xie, BC Edmison… - Blood, The Journal …, 2021 - ashpublications.org
Decreased cytomegalovirus (CMV)-specific immunity after hematopoietic cell transplantation
(HCT) is associated with late CMV reactivation and increased mortality. Whether letermovir …

Effect of preemptive therapy vs antiviral prophylaxis on cytomegalovirus disease in seronegative liver transplant recipients with seropositive donors: a randomized …

N Singh, DJ Winston, RR Razonable, GM Lyon… - Jama, 2020 - jamanetwork.com
Importance Despite the use of a cytomegalovirus (CMV) prevention strategy of antiviral
prophylaxis for high-risk CMV-seronegative liver transplant recipients with seropositive …

Poxvirus vectored cytomegalovirus vaccine to prevent cytomegalovirus viremia in transplant recipients: a phase 2, randomized clinical trial

I Aldoss, C La Rosa, LR Baden, J Longmate… - Annals of internal …, 2020 - acpjournals.org
Background: Triplex vaccine was developed to enhance cytomegalovirus (CMV)–specific T
cells and prevent CMV reactivation early after hematopoietic stem cell transplant (HCT) …

Clinical “real‐world” experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients

A Anderson, M Raja, N Vazquez, M Morris… - Clinical …, 2020 - Wiley Online Library
Background Letermovir was approved in 2017 for prevention of cytomegalovirus (CMV)
infection in seropositive (R+) allogeneic hematopoietic cell transplantation (HCT) patients …

Immunoprofiling reveals cell subsets associated with the trajectory of cytomegalovirus reactivation post stem cell transplantation

L Stern, HM McGuire, S Avdic… - Nature …, 2022 - nature.com
Human cytomegalovirus reactivation is a major opportunistic infection after allogeneic
haematopoietic stem cell transplantation and has a complex relationship with post …

Clinical experience with a novel assay measuring cytomegalovirus (CMV)-specific CD4+ and CD8+ T-cell immunity by flow cytometry and intracellular cytokine …

R Rogers, K Saharia, A Chandorkar, ZF Weiss… - BMC infectious …, 2020 - Springer
Background Cytomegalovirus (CMV) infection is one of the most common opportunistic
infections following organ transplantation, despite administration of CMV prophylaxis. CMV …

Robust CD4+ T-cell recovery in adults transplanted with cord blood and no antithymocyte globulin

I Politikos, JA Lavery, P Hilden, C Cho, T Borrill… - Blood …, 2020 - ashpublications.org
Quality of immune reconstitution after cord blood transplantation (CBT) without
antithymocyte globulin (ATG) in adults is not established. We analyzed immune recovery in …

Immune control of cytomegalovirus reactivation in stem cell transplantation

MA Degli-Esposti, GR Hill - Blood, The Journal of the American …, 2022 - ashpublications.org
The reactivation of viruses from latency after allogeneic stem cell transplantation (SCT)
continues to represent a major clinical challenge requiring sophisticated monitoring …